On Wednesday, Great Basin Scientific Inc (NASDAQ:GBSN)’s shares declined -19.09% to $0.0589.
Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company, declared recently that it has retained Roth Capital Partners as financial advisor to assist in a restructuring of the Company’s Series C Warrants. The Series C Warrants were issued as part of the Unit offering the Company accomplished on March 2, 2015. The Company is also preparing to file a proxy statement and hold a special shareholder meeting to seek approval to effect a reverse stock split and authorize additional common shares to meet its obligation to deliver common shares under the cashless exercise provision of the Series C Warrants.
Great Basin Scientific, Inc., a molecular diagnostic testing company, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections.
Charles Schwab Corp (NYSE:SCHW)’s shares gained 0.94% to $31.11.
The Charles Schwab Corporation released its Monthly Activity Report recently. Company highlights for the month of August 2015 comprise:
- Net new assets brought to the company by new and existing clients in August 2015 totaled $9.2 billion.
- Total client assets were $2.46 trillion as of month-end August, up 1% from August 2014 and down 4% contrast to July 2015.
- Average interest-earning assets on the company’s balance sheet were a record $160.6 billion in August, up 16% from August 2014 and up 2% contrast to July 2015.
The Charles Schwab Corporation, through its auxiliaries, provides wealth administration, securities brokerage, banking, money administration, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services.
At the end of Wednesday’s trade, Silver Wheaton Corp. (USA) (NYSE:SLW)‘s shares surged 7.12% to $12.33.
Silver Wheaton Corp. (SLW) declares that it intends to make a normal course issuer bid (a “NCIB”) to purchase up to 20,229,671 common shares of Silver Wheaton (the “Common Shares”) on the Toronto Stock Exchange (the “TSX”) and New York Stock Exchange (the “NYSE”).
The NCIB has been approved by the Company’s board of directors; however, it is subject to acceptance by the TSX and, if accepted, will be made in accordance with the applicable rules and policies of the TSX and the NYSE, and applicable Canadian and U.S. securities laws. Under the NCIB, Common Shares may be repurchased in open market transactions on the TSX, the NYSE, and/or other Canadian or United States exchanges, or by such other means as may be permitted by the TSX and/or the NYSE and applicable Canadian and U.S. securities laws. The price that Silver Wheaton will pay for Common Shares in open market transactions will be the market price at the time of purchase.
In accordance with TSX rules, any daily purchases (other than following a block purchase exception) on the TSX under the NCIB are limited to a maximum of 320,441 Common Shares, which represents 25% of the average daily trading volume on the TSX for the six months ended August 31, 2015. Daily purchases (other than following a block purchase exception) on the NYSE under the NCIB are limited to 25% of the average daily trading volume for the preceding four weeks. Any Common Shares that are purchased under the NCIB will be cancelled.
Silver Wheaton Corp. operates as a precious metals streaming company worldwide. The company has 18 long-term purchase agreements and 1 early deposit long-term purchase agreement associated with silver and gold regarding27 various mining assets.
Abbott Laboratories (NYSE:ABT), ended its Wednesday’s trading session with 0.11% gain, and closed at $43.86.
Abbott (ABT) declared it received Health Canada’s approval of the TECNIS® Symfony Extended Range of Vision intraocular lens (IOL) for the treatment of people with cataracts who may also have a diminished ability to focus on near objects (presbyopia). It is the first and only extended range of vision IOL to correct presbyopia and assist people with cataracts see better at all distances, counting far, intermediate and near, and points in between, with reduced need for glasses.1,2
A cataract is a gradual clouding of the natural lens of the eye that prevents light from reaching the retina.3 More than 2.5 million Canadians have cataracts. The incidence of cataracts enhances with age from about 12 per cent at age 50, to 60 per cent at age 70.5 In general, about 50 per cent of Canadians 65 years of age or older have cataracts.
Traditionally after cataract surgery, people may still require eyeglasses.7, 8 However, a clinical study of 31 people who had the TECNIS Symfony IOL implanted showed 70 per cent of them reporting rarely or never requiring wearing glasses. One hundred per cent of people who had the lens implanted stated they did not need to wear glasses for seeing objects at distance, while 94 per cent and 87 per cent of people stated the same results at intermediate and near distances, respectively.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.